Merck: Buy The Weakness

Group 1 - Merck has significantly underperformed the market in recent years, primarily due to the impending loss of exclusivity for its key drug Keytruda and several costly acquisitions [2] - The company is facing challenges that may impact its future performance, particularly with the expiration of patents on important products [2] Group 2 - The Value Portfolio focuses on constructing retirement portfolios through a fact-based research strategy, which includes thorough analysis of 10Ks, analyst commentary, market reports, and investor presentations [2]